Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every front....
myTomorrows et Emmaus Life Sciences, Inc. (« Emmaus ») annoncent la disponibilité de la L-glutamine de grade pharmaceutique (poudre pour suspension...
myTomorrows und Emmaus Life Sciences, Inc. ("Emmaus") geben die Verfügbarkeit eines Programms für den frühzeitigen Zugang zu pharmazeutischem...
myTomorrows y Emmaus Life Sciences, Inc. ("Emmaus") anuncian la disponibilidad de un programa de acceso temprano a la L-glutamina (polvo oral) de...
myTomorrows, a company that makes pre-approval medicines available to patients with an unmet medical need, announces today that Martin Naley has...
myTomorrows announces that Ronald Plasterk, a renowned molecular geneticist and until recently Dutch Minister of the Interior and Kingdom Relations,...
myTomorrows announces that Ashley Vinson, former Head of Brand Strategy at Twitter, joins the company as Chief Marketing Officer. Robert-Jan Sips,...
Das erste zugelassene Produkt aus dem Portfolio von myTomorrows, das denjenigen, die dringende medizinische Hilfe benötigen, weiterhin zugänglich...
Primo prodotto registrato nel portafoglio di myTomorrows, destinato a offrire continuità d'accesso a chiunque debba fronteggiare urgenti esigenze...
myTomorrows asume de manera exclusiva la responsabilidad de la promoción en Europa de Zevalin® (ibritumomab tiuxetan), el tratamiento de...
Premier produit enregistré dans le portefeuille de myTomorrows à maintenir son accès aux personnes confrontées à des besoins médicaux urgents....
First registered product in the myTomorrows portfolio, to continue access for those facing urgent medical needs. MyTomorrows, a company facilitating...
myTomorrows, global online facilitator of early access to investigational drugs, has introduced an openly accessible API to open up its comprehensive ...
myTomorrows gab heute bekannt, dass Robert Kraal (41) mit sofortiger Wirkung zum Chief Operating Officer ernannt wurde. Als COO wird Kraal für die...
myTomorrows today announced that Robert Kraal (41) has been named Chief Operating Officer, effective immediately. As COO Robert will be responsible...
myTomorrows a annoncé aujourd'hui la nomination avec effet immédiat de Robert Kraal (41 ans) au poste de chef de l'exploitation. Dans le cadre de ses ...
myTomorrows ha anunciado hoy que Robert Kraal (41) ha sido nombrado director de Operaciones, con efectividad inmediata. Como director de Operaciones, ...
myTomorrows (Amsterdam, the Netherlands) today announced that Dr. James Shannon will join its supervisory board, effective immediately. "James'...
myTomorrows (Ámsterdam, Holanda) anunció hoy que ha firmado recientemente un contrato de colaboración con Hemispherx Biopharma, Inc. (Filadelfia, EE. ...
myTomorrows (Amsterdam, the Netherlands) announced today that it has recently signed a contract to collaborate with Hemispherx Biopharma, Inc....
A myTomorrows (Amsterdã, Holanda) anunciou hoje que assinou recentemente um contrato de colaboração com a Hemispherx Biopharma, Inc. (Filadélfia,...
- myTomorrows anuncia un acuerdo con Spectrum para un programa de acceso temprano a inyección de pralatrexato para pacientes con linfoma de célula T...
myTomorrows (Amsterdam, Pays-Bas) a le plaisir d'annoncer la signature d'un accord avec Spectrum Pharmaceuticals, Inc. (Henderson, Nevada, USA) dans...
myTomorrows (Amsterdam, Niederlande) freut sich, die Unterzeichnung eines Vertrages mit Spectrum Pharmaceuticals, Inc. (Spectrum Pharmaceuticals...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.